ストックスクリーナーアプリを入手
7.03
3.53%
0.24
アフターアワーズ：
7.00
-0.03
-0.43%
前日終値:
$6.79
開ける：
$6.76
24時間の取引高:
1.67M
Relative Volume:
0.78
時価総額：
$499.63M
収益：
$409.00K
当期純損益:
$-101.35M
株価収益率:
-4.3129
EPS:
-1.63
ネットキャッシュフロー:
$-71.49M
1週間 パフォーマンス:
-4.48%
1か月 パフォーマンス:
+12.84%
6か月 パフォーマンス:
-3.70%
1年 パフォーマンス:
+156.57%
1日の値動き範囲:
$6.64
$7.03
1週間の範囲:
$6.45
$7.31
52週間の値動き範囲:
$2.315
$14.84
Altimmune Inc Stock (ALT) Company Profile
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-29 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-01-24 | 開始されました | Goldman | Neutral |
| 2023-03-22 | ダウングレード | Goldman | Buy → Neutral |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-11 | 開始されました | Guggenheim | Buy |
| 2020-12-14 | 開始されました | Jefferies | Buy |
| 2020-11-12 | 繰り返されました | B. Riley Securities | Buy |
| 2020-09-25 | 開始されました | B. Riley FBR | Buy |
| 2020-08-14 | 開始されました | Evercore ISI | Outperform |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-07-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-02-24 | 再開されました | ROTH Capital | Buy |
| 2019-07-19 | 開始されました | ROTH Capital | Buy |
| 2017-10-09 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Altimmune Inc (ALT) 最新ニュース
Altimmune (ALT) to Release Quarterly Earnings on Tuesday - MarketBeat
Altimmune’s stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss - MSN
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 - StockTitan
Thinking about buying stock in Minim, Aurora Innovation, Altimmu - GuruFocus.com
Altimmune Awaits Results Of Fatty Liver Disease Drug Pemvidutide - RTTNews
Altimmune (NASDAQ:ALT) Trading Up 7%Here's What Happened - MarketBeat
Altimmune (ALT) Price Target Increased by 9.39% to 19.53 - MSN
Regulatory And Clinical Catalysts Ahead For Altimmune (NASDAQ:ALT) - Seeking Alpha
When (ALT) Moves Investors should Listen - Stock Traders Daily
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: C - GuruFocus.com
Altimmune Jumps 66% After Positive Results for Its Obesity Drug - MSN
Altimmune, Inc. (NASDAQ:ALT) Receives $18.80 Average Target Price from Brokerages - MarketBeat
SG Americas Securities LLC Sells 220,135 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
State Street Corp's Strategic Reduction in Altimmune Inc Holdings - Yahoo Finance
Altimmune, Inc. (ALT): A Bull Case Theory - MSN
Exchange Traded Concepts LLC Has $1.33 Million Position in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Millennium Management LLC Increases Stake in Altimmune Inc - Yahoo Finance
Altimmune (NASDAQ:ALT) Trading Up 10.7%Should You Buy? - MarketBeat
Learn to Evaluate (ALT) using the Charts - Stock Traders Daily
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024 - The Manila Times
Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Where are the Opportunities in (ALT) - Stock Traders Daily
Consider Buying Potential Takeover Target Altimmune (NASDAQ:ALT) - Seeking Alpha
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference - The Manila Times
Altimmune completes enrollment for MASH treatment trial By Investing.com - Investing.com South Africa
Altimmune completes enrollment for MASH treatment trial - Investing.com India
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) - The Manila Times
Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis - Marketscreener.com
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Profund Advisors LLC Sells 94,081 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Wall Street SWOT: Altimmune stock rides wave of promising obesity drug data - Investing.com
Logos Global Management LP Sells 750,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Altimmune Inc [ALT] Investment Guide: What You Need to Know - Knox Daily
Farallon Capital Management LLC Has $184,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
SEC Form FWP filed by Alta Global Group Limited - Quantisnow
How the (ALT) price action is used to our Advantage - Stock Traders Daily
Unique Fabricating (NYSEAMERICAN:UFAB) Trading Down 17.6% - Defense World
StockWatch: FDA Surprise Lifts Expectations for Applied’s Govorestat - Genetic Engineering & Biotechnology News
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects (NASDAQ:ALT) - Seeking Alpha
Altimmune (NASDAQ:ALT) Trading Up 3.7% - MarketBeat
Milan Fashion Week: At Gucci, making fashion wearable - CNA Luxury
The Best Celebrity Shoes at Gucci’s Spring 2025 Show in Milan: Kirsten Dunst, Lucky Blue Smith, Nara Smith and More - Footwear News
"Commit To It and Do It": Mel and Lyas Gather the Girls for a Gucci SS25 Debrief - Interview
Take a look at celebrities' outfits for Milan Fashion Week's Gucci show - Marca English
Sabato swings into the sixties: What went down at Gucci SS25 - Dazed
TikTok Star Nara Smith Stuns at Gucci’s Spring 2025 Show in Patent Leather Signoria Slingback Pumps at Milan Fashion Week - Yahoo Entertainment
Applied Therapeutics stock surges after FDA update - The Pharma Letter
Altimmune (NASDAQ:ALT) Trading Down 4.5% - MarketBeat
Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club - The Motley Fool
Altimmune Inc (ALT) 財務データ
収益
当期純利益
現金流量
EPS
Altimmune Inc (ALT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Drutz David | Director |
Aug 19 '24 |
Sale |
6.90 |
16,011 |
110,547 |
41,958 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
44,990 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
39,016 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
55,965 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
49,991 |
| Garg Vipin K | President and CEO |
Feb 02 '24 |
Option Exercise |
0.00 |
18,950 |
0 |
300,404 |
| Garg Vipin K | President and CEO |
Feb 01 '24 |
Option Exercise |
0.00 |
16,545 |
0 |
288,767 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
29,699 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
43,277 |
| Garg Vipin K | President and CEO |
Jan 30 '24 |
Option Exercise |
0.00 |
26,775 |
0 |
276,030 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):